Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 13/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24002470 | 0.90 | TRPM8 (0.46) | TRPM8ALDH1A1SMN1; SMN2POLBMAPT | |
| SCHEMBL24002418 | 0.89 | MAPT (0.51) | TRPM8ALDH1A1SMN1; SMN2POLBMAPT | |
| SCHEMBL21789052 | 0.88 | TRPM8 (0.44) | TRPM8ALDH1A1SMN1; SMN2POLBMAPT | |
| SCHEMBL21789058 | 0.87 | PPARG (0.47) | TRPM8ALDH1A1SMN1; SMN2POLBMAPT | |
| SCHEMBL21789268 | 0.87 | PPARG (0.47) | TRPM8ALDH1A1SMN1; SMN2POLBMAPT | |
| SCHEMBL21789284 | 0.87 | PPARG (0.47) | TRPM8ALDH1A1SMN1; SMN2POLBMAPT | |
| SCHEMBL21789053 | 0.84 | POLB (0.46) | TRPM8ALDH1A1POLBMAPTNPSR1 | |
| SCHEMBL21777274 | 0.83 | ALDH1A1 (0.41) | TRPM8ALDH1A1SMN1; SMN2POLBMAPT | |
| SCHEMBL21789056 | 0.81 | POLB (0.46) | TRPM8ALDH1A1SMN1; SMN2POLBMAPT | |
| SCHEMBL21789051 | 0.81 | POLB (0.46) | TRPM8ALDH1A1SMN1; SMN2POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210346367-A1 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-11-11 | — | — | US | disclosed |
| WO-2020047251-A1 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346367-A1 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | OGT, OGA, UGGT1 | TRPM8 3740/4885ALDH1A1 1594/4885SMN1; SMN2 3231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.